Fiji vs Suriname: Access to anti-retroviral drugs, male
Fiji
28.0%
in 2024
Suriname
41.0%
in 2024
Fiji rank
133rd
Suriname rank
130th
Access to anti-retroviral drugs, male over time
- Fiji
- Suriname
How they compare
Suriname currently reports 41.0% against 28.0% in Fiji, a difference of 13.0%.
That makes Suriname's figure about 1.5 times Fiji's.
The two have swapped places 2 times across 25 shared years of data; in 2000 it was Suriname ahead.
Fiji ranks 133rd and Suriname ranks 130th of 141 countries.
Across the 3 decades both report, Fiji averaged higher in 2 and Suriname in 1.
Head to head by decade
| Decade | Fiji | Suriname | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 41.2% | 5.6% | 35.6% | Fiji |
| 2010s | 33.5% | 25.2% | 8.3% | Fiji |
| 2020s | 19.6% | 37.6% | 18.0% | Suriname |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, male, Fiji or Suriname?
- Suriname, at 41.0% against 28.0% in Fiji as of 2024.
- What is the difference in access to anti-retroviral drugs, male between Fiji and Suriname?
- 13.0%, with Suriname ahead.
- How many years of comparable data are there for Fiji and Suriname?
- 25 years are reported by both, from 2000 to 2024.
- How do Fiji and Suriname rank globally for access to anti-retroviral drugs, male?
- Fiji ranks 133rd and Suriname ranks 130th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult males living with HIV who are receiving antiretroviral therapy.